Jordan Jones1,2,3, Megan Wetzel1,2,3, Timothy Brown1,2,3, Jae Jung1,2,3. 1. Drs. Jones and Brown are with the Division of Dermatology of the Department of Medicine at the University of Louisville in Louisville, Kentucky. 2. Dr. Wetzel is with Neighborhood Dermatology in Plano, Texas. 3. Dr. Jung is with the Norton Cancer Institute in Louisville, Kentucky.
Abstract
BACKGROUND: Patients with advanced cutaneous squamous cell carcinoma (cSCC) frequently have high tumor mutation burdens (TMBs) but cannot tolerate immunotherapy due to comorbid conditions or already immunosuppressed states. OBJECTIVE: We considered whether these patients might be good candidates for targeted therapy if unique genetic mutations are identified. METHODS: Biopsies of primary tumors or metastases of advanced cSCC from seven patients were sent for FoundationOne testing. Genomic alterations and TMBs were compiled from these samples and used to tailor therapy when possible. Patients were followed for changes in their disease burden. RESULTS: Eight biopsies taken from seven patients were sent for FoundationOne testing. Sixty-three genomic alterations were identified. Thirteen genes had mutations occur more than once, with mutations in TP53 being the most frequently identified (100% of patients). In one patient, an ERBB3 mutation was identified, and lapatinib was added to nivolumab for a six-month course of treatment, after which point the patient experienced stabilization of disease without progression for two years as of the most recent follow-up. CONCLUSION: More routine investigation of cSCC tumors with next-generation sequencing can help to identify unique mutations that respond favorably to targeted therapy in these notoriously difficult-to-treat malignancies.
BACKGROUND:Patients with advanced cutaneous squamous cell carcinoma (cSCC) frequently have high tumor mutation burdens (TMBs) but cannot tolerate immunotherapy due to comorbid conditions or already immunosuppressed states. OBJECTIVE: We considered whether these patients might be good candidates for targeted therapy if unique genetic mutations are identified. METHODS: Biopsies of primary tumors or metastases of advanced cSCC from seven patients were sent for FoundationOne testing. Genomic alterations and TMBs were compiled from these samples and used to tailor therapy when possible. Patients were followed for changes in their disease burden. RESULTS: Eight biopsies taken from seven patients were sent for FoundationOne testing. Sixty-three genomic alterations were identified. Thirteen genes had mutations occur more than once, with mutations in TP53 being the most frequently identified (100% of patients). In one patient, an ERBB3 mutation was identified, and lapatinib was added to nivolumab for a six-month course of treatment, after which point the patient experienced stabilization of disease without progression for two years as of the most recent follow-up. CONCLUSION: More routine investigation of cSCC tumors with next-generation sequencing can help to identify unique mutations that respond favorably to targeted therapy in these notoriously difficult-to-treat malignancies.
Authors: Ayse Selen Yilmaz; Hatice Gulcin Ozer; Jessica L Gillespie; Dawn C Allain; Madison N Bernhardt; Karina Colossi Furlan; Leticia T F Castro; Sara B Peters; Priyadharsini Nagarajan; Stephen Y Kang; O Hans Iwenofu; Thomas Olencki; Theodoros N Teknos; Amanda Ewart Toland Journal: Cancer Date: 2016-12-01 Impact factor: 6.860
Authors: Edward Roper; Trina Lum; Carsten E Palme; Bruce Ashford; Sydney Ch'ng; Marie Ranson; Michael Boyer; Jonathan Clark; Ruta Gupta Journal: Pathology Date: 2017-06-27 Impact factor: 5.306
Authors: Yvonne Y Li; Glenn J Hanna; Alvaro C Laga; Robert I Haddad; Jochen H Lorch; Peter S Hammerman Journal: Clin Cancer Res Date: 2015-01-14 Impact factor: 12.531
Authors: L Di Nardo; C Pellegrini; A Di Stefani; L Del Regno; P Sollena; A Piccerillo; C Longo; C Garbe; M C Fargnoli; K Peris Journal: J Eur Acad Dermatol Venereol Date: 2020-01-23 Impact factor: 6.166
Authors: F F Gellrich; S Hüning; S Beissert; T Eigentler; E Stockfleth; R Gutzmer; F Meier Journal: J Eur Acad Dermatol Venereol Date: 2019-12 Impact factor: 6.166
Authors: Curtis R Pickering; Jane H Zhou; J Jack Lee; Jennifer A Drummond; S Andrew Peng; Rami E Saade; Kenneth Y Tsai; Jonathan L Curry; Michael T Tetzlaff; Stephen Y Lai; Jun Yu; Donna M Muzny; Harshavardhan Doddapaneni; Eve Shinbrot; Kyle R Covington; Jianhua Zhang; Sahil Seth; Carlos Caulin; Gary L Clayman; Adel K El-Naggar; Richard A Gibbs; Randal S Weber; Jeffrey N Myers; David A Wheeler; Mitchell J Frederick Journal: Clin Cancer Res Date: 2014-10-10 Impact factor: 12.531
Authors: Giulia Bertino; Ales Groselj; Luca G Campana; Christian Kunte; Hadrian Schepler; Julie Gehl; Tobian Muir; James A P Clover; Pietro Quaglino; Erika Kis; Matteo Mascherini; Brian Bisase; Giancarlo Pecorari; Falk Bechara; Paolo Matteucci; Joy Odili; Francesco Russano; Antonio Orlando; Rowan Pritchard-Jones; Graeme Moir; David Mowatt; Barbara Silvestri; Veronica Seccia; Werner Saxinger; Francesca de Terlizzi; Gregor Sersa Journal: Front Oncol Date: 2022-09-20 Impact factor: 5.738